Financials data is unavailable for this security.
View more
Year on year Burning Rock Biotech Ltd had revenues fall -4.58% from 563.24m to 537.44m, though the company grew net income from a loss of 971.23m to a smaller loss of 653.69m.
| Gross margin | 67.71% |
|---|---|
| Net profit margin | -111.18% |
| Operating margin | -114.20% |
| Return on assets | -48.15% |
|---|---|
| Return on equity | -68.89% |
| Return on investment | -65.09% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Burning Rock Biotech Ltd fell by 310.05m. Cash Flow from Investing was negative at 9.30m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 255.78m for operations while cash used for financing totalled 48.83m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 9.14 |
|---|---|
| Tangible book value per share | 9.13 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.11 |
|---|---|
| Quick ratio | 2.85 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
